Integrated care to improve outcomes after early liver transplant for alcohol-related liver disease
Official title: 1/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease
Funded at Ut Southwestern Medical Center · NIH-11144380 · Data updated 2026-11-12
Looking at whether coordinated liver and addiction care helps people with alcohol-related liver disease who receive early liver transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $430,228 |
| NIH project number | 5R01AA030956-03 |
| Project ID | NIH-11144380 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with alcohol-associated liver disease who are being evaluated for or have received an early liver transplant (generally with less than six months of alcohol abstinence) are the ideal candidates.
✕Less likely to help
People without alcohol-related liver disease, those not undergoing transplant evaluation, or patients who are unwilling or unable to engage in integrated addiction care are unlikely to benefit from this study.
What this research studies
If you have alcohol-related liver disease and are being considered for an early liver transplant, this project follows you at several transplant centers to collect medical, behavioral, and social information. The team will document who gets referred for early transplant, use validated questionnaires and clinical tests to measure biopsychosocial factors, and build models that predict outcomes after transplant. They will compare results for patients who receive integrated addiction and liver care versus usual care across multiple centers. Patients and transplant teams help choose which measures matter and how follow-up is done.
Why it matters
Potential benefit: If successful, this work could decrease relapse and improve survival and quality of life by standardizing integrated addiction and transplant care for people receiving early liver transplants.
How similar studies have gone: Retrospective studies of early liver transplant for severe alcohol-associated hepatitis have shown acceptable outcomes, but prospective multicenter work including biopsychosocial measures is novel and less tested.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Vanwagner, Lisa B — Ut Southwestern Medical Center
- Study coordinator: Vanwagner, Lisa B
Related research
Other NIH-funded projects on the same topics.
-
Targeting a specific CD38 form to protect livers from injury after transplant
A new approach tests a selective drug to protect donor livers from injury during transplant, potentially increasing usable organs and improving transplant outcomes.
-
Regulatory dendritic cell therapy to reduce immunosuppressive drugs after liver transplant
A new approach using donor-derived regulatory dendritic cells is being tested to help adults who receive a liver transplant live without relying on traditional immunosuppressive drugs.
-
HOPE liver transplant: reducing infections and cancer risk for HIV-positive recipients
This grant aims to better understand why HIV-positive liver transplant recipients face higher infection and cancer risks and to improve safety and outcomes for these patients.
-
Early liver transplant decisions for severe alcohol-related liver disease
A large study follows adults with severe alcohol-related liver disease to understand how to best select and manage patients for early liver transplantation.
-
Early Liver Transplant for Severe Alcoholic Hepatitis
A hospital-based program is studying whether offering an early liver transplant to patients with severe alcoholic hepatitis can save lives when standard medical treatment fails.
-
Early liver transplant for severe alcoholic hepatitis (SAH) to save lives
A Johns Hopkins program is testing whether giving an early liver transplant to patients with severe alcoholic hepatitis who can’t be helped by standard treatments can save lives and reduce relapse risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.